Clinical effect and mechanism of lyophilized recombinant human brain natriuretic peptide in treatment of patients with cardiac insufficiency

Objective To explore the clinical effect and mechanism of lyophilized recombinant human brain natriuretic peptide in treatment of patients with cardiac insufficiency. Methods 82 patients hospitalized with heart failure were randomly divided into an observation group and a control group, 41 cases for each group. The control group was conventionally treated; in addition, the observation group was treated with new active element. Both groups were treated 7 d. The efficacy, stroke volume (SV), left ventricular ejection fraction (LVEF), central venous pressure (CVP), the nitric oxide (NO), endothelin-1 (ET-1), and N-terminal brain natriuretic peptide (NT-proBNP) before and after treatment, and the adverse reactions during treatment were compared between these two groups. Results The total effective rate of the observation group (92.68%) was higher than that of the control group (73.17%), with a statistical difference (P 0.05). The LVEF, SV, and NO significantly increased and CVP, NT-proBNP, and ET-1 decreased in both groups after treatment, with statistical differences (P<0.05). After treatment, the LVEF, SV, and NO were higher and CVP, NT-proBNP, and ET-1 were lower in the observation than in the control group (P<0.05). No serious drug adverse reactions occurred in both groups during treatment. Conclusions Lyophilized recombinant human brain natriuretic for heart failure is safe and effective. The mechanism may be that it improves vascular endothelial function. Key words: Lyophilized recombinant human brain natriuretic; Heart failure; Effect